TEL AVIV, Israel, June 17 /PRNewswire-FirstCall/ -- BSP Ltd., (http://www.bsp.co.il/pressall.asp) an Israeli company which develops and markets systems for non-invasive diagnosis and monitoring of Ischemic Heart Disease, announced that they successfully raised $2.6 million in a private funding round, that included existing shareholders in the company as well as new investors.
BSP developed the HyperQ(TM), a cutting-edge technology that offers highly reliable, low-cost and risk free cardiac monitoring for broad populations and allows, for the first time, effective and accurate testing for Ischemic Heart Disease - the No. 1 killer in the world.
Thousands of patients in Israel, Europe and the US have already been examined by HyperQ(TM) Stress Systems in controlled clinical studies, pilot programs and routine testing. The results have demonstrated the system's high efficiency and unmatched accuracy in the diagnosis of IHD. The HyperQ(TM) system received FDA clearance (510K), as well as the European CE marking.
The company has entered the clinical and commercial phase, during which the HyperQ(TM) Stress System will be integrated in inpatient and outpatient hospital settings, private doctor offices and major research centers.
Further applications on the company's scope; include bedside monitors for ischemic events; devices for cardiac home-care and telemedicine; and the implementation of the HyperQ(TM) technology in implantable cardiac devices.
"The completion of this round reflects our investors' ongoing confidence in our ability to meet our commercial and clinical milestones. This round will enable us to step-up the marketing and business development efforts in the US, and accelerate development of BSP's next application - the HyperQ bedside monitor," said Dr. Amir Beker, CEO of BSP.
Dr. Beker added, "The HyperQ(TM) technology is a revolutionary non-invasive solution to today's most fatal pathology. It improves the standard of care for cardiac patients, decreases the risk of further, often invasive, tests, and addresses the dire needs of private and national healthcare systems to balance the immense costs of cardiac diagnosis and monitoring."
BSP is dedicated to providing novel, risk free and highly reliable solutions for the diagnosis and monitoring of Ischemic Heart Disease. BSP was founded in 2000 by Dr. Amir Beker and Mr. Ariel Landau and has completed a successful IPO in mid-2006 and its shares are traded on the Tel Aviv Stock Exchange. Visit: http://www.bspmedical.com
Contact: Dr. Amir Beker, CEO or Dr. Neri Malka, Head of Clinical Marketing: +972-3-6474840
|SOURCE BSP - Biological Signal Processing Ltd|
Copyright©2008 PR Newswire.
All rights reserved